HEAL Initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development (R61/R33 - Clinical Trial Not Allowed)

Funding Opportunity RFA-HL-20-031 from the NIH Guide for Grants and Contracts. This FOA invites applications for pre-clinical research to stimulate the development of novel, mechanism-based pharmacotherapies to selectively reverse breathing suppression produced by opioids. Two critical phases of pre-clinical investigation are supported. Phase I: the identification and rigorous validation of candidate targets; Phase II: development of therapeutic candidates, such as small molecules, biologics, and natural products that modulate validated targets identified in Phase I, using relevant animal models or human cells/tissue. Specific Phase I and II milestones, which will be formalized pre-award and serve as a schedule of performance expectations to maximize the output from each phase of the study. Milestone performance will be a major factor in determining which applications will be selected to transition from Phase I to Phase II. Phase II extends up to addressing preclinical functional outcomes, toxicology, and pharmacokinetics needed to support an Investigational New Drug (IND) application. Multi-disciplinary, multiple PI teams combining expertise in respiratory neurobiology, opioid pharmacology and pre-clinical drug development are strongly encouraged. This FOA is intended for pharmacotherapeutic development. Projects proposing device and model development or validation, the elucidation of biological mechanisms, population-based epidemiology, or human subjects research would n...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding